Ph3 LY4064809 + Endocrine Therapy + CDK4/6 inh HR+/HER2-Breast w/ PIK3CA (PIKALO-2)

A Phase 3 Randomized Double-Blind Placebo-Controlled Study of LY4064809 Combined with a CDK4/6 Inhibitor and Endocrine Therapy in Adults with HR+ HER2- Advanced Breast Cancer with a PIK3CA Mutation Who Received No Prior Treatment for Advanced Breast Cancer (PIKALO-2) J6M-MC-JSGD